These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 32828071)

  • 1. Variability in combinations of APTT reagent and substrate plasma for a one-stage clotting assay to measure factor VIII products.
    Suzuki A; Suzuki N; Kanematsu T; Okamoto S; Suzuki N; Tamura S; Kikuchi R; Katsumi A; Kojima T; Matsushita T
    Int J Lab Hematol; 2024 Aug; 46(4):705-713. PubMed ID: 38426662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global coagulation assays in hemophilia A: A comparison to conventional assays.
    Aghighi S; Riddell A; Lee CA; Brown SA; Tuddenham E; Chowdary P
    Res Pract Thromb Haemost; 2020 Feb; 4(2):298-308. PubMed ID: 32110761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating Factor VIII Concentrates Using Clot Waveform Analysis.
    Wada H; Shiraki K; Matsumoto T; Shimpo H; Sakano Y; Nishii H; Tamaki S; Suzuki K; Tawara I; Yamashita Y; Shimaoka M
    J Clin Med; 2024 Jun; 13(13):. PubMed ID: 38999423
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis.
    Kanouchi K; Narimatsu H; Shirata T; Morikane K
    Health Sci Rep; 2021 Jun; 4(2):e258. PubMed ID: 33738342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the phenotypic severity of hemophilia A: using rotational thromboelastometry (ROTEM) and APTT-clot waveform analysis.
    Gupta D; Arya V; Dass J; Gupta N; Kalra M; Sachdeva A; Kotwal J
    Blood Res; 2024 May; 59(1):19. PubMed ID: 38743166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Clot Waveform Analysis and Related Parameters in the Diagnosis and Treatment of Hemophilia A.
    Song G; Wang Y; Zhang L; Xia M
    Thromb Haemost; 2024 Apr; ():. PubMed ID: 38626899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are shortened aPTT values always to be attributed only to preanalytical problems?
    Radišić Biljak V; Tomas M; Lapić I; Saračević A
    Diagnosis (Berl); 2024 May; ():. PubMed ID: 38696342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan.
    Shinozawa K; Yada K; Kojima T; Nogami K; Taki M; Fukutake K; Yoshioka A; Shirahata A; Shima M;
    Thromb Haemost; 2021 May; 121(5):603-615. PubMed ID: 33254277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitor Index in the Clot Waveform Analysis-Based Mixing Test Differentiates among Hemophilia A without and with Inhibitors, and Lupus Anticoagulant.
    Shimonishi N; Ogiwara K; Oda Y; Kawabe T; Emmi M; Shima M; Nogami K
    Thromb Haemost; 2021 Jun; 121(6):792-799. PubMed ID: 33412612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A.
    Takeyama M; Furukawa S; Yada K; Ogiwara K; Shimonishi N; Nakajima Y; Mizumachi K; Noguchi-Sasaki M; Shima M; Nogami K
    Thromb Haemost; 2021 Oct; 121(10):1289-1298. PubMed ID: 33641138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype.
    Milos M; Coen Herak D; Mahmoud Hourani Soutari N; Pavic J; Zupancic-Salek S; Zadro R; Antovic JP
    Int J Lab Hematol; 2021 Apr; 43(2):273-280. PubMed ID: 32964648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in laboratory assessment of thrombosis and hemostasis.
    Song J
    Blood Res; 2022 Apr; 57(S1):93-100. PubMed ID: 35483933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19.
    Onishi T; Shimonishi N; Takeyama M; Furukawa S; Ogiwara K; Nakajima Y; Kasahara K; Nishio K; Yoshimoto K; Inoue S; Kawaguchi M; Fukushima H; Saito Y; Yoshiji H; Muro S; Tsuruya K; Okada S; Sugie K; Kawaguchi R; Nishikubo T; Yamazaki M; Oda Y; Kawabe T; Onishi K; Nishio T; Nogami K
    Int J Hematol; 2022 Jun; 115(6):826-837. PubMed ID: 35171446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Assessment of Factor VIII Activity by Template Matching Utilizing Weighted Average Parameters from Comprehensive Clot Waveform Analysis.
    Shimonishi N; Ogiwara K; Oda Y; Kawabe T; Okazaki S; Shima M; Nogami K
    Thromb Haemost; 2021 Feb; 121(2):164-173. PubMed ID: 32828071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
    Matsumoto T; Shima M; Takeyama M; Yoshida K; Tanaka I; Sakurai Y; Giles AR; Yoshioka A
    J Thromb Haemost; 2006 Feb; 4(2):377-84. PubMed ID: 16420569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.
    Matsumoto T; Nogami K; Tabuchi Y; Yada K; Ogiwara K; Kurono H; Arai N; Shima M
    Haemophilia; 2017 Sep; 23(5):e427-e435. PubMed ID: 28750470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis.
    Shima M
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):125-31. PubMed ID: 14872433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factor VIII assays in treated hemophilia A patients].
    Lasne D; Pouplard C; Nougier C; Eschwege V; Le Cam Duchez V; Proulle V; Smahi M; Harzallah I; Voisin S; Toulon P; Sobas F; Galinat H; Flaujac C; Ternisien C; Jeanpierre E;
    Ann Biol Clin (Paris); 2019 Feb; 77(1):53-65. PubMed ID: 30799298
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.